Sort   by:  
 Page size 
MetabolomicsGeographic variation of mutagenic exposures in kidney cancer genomes

International differences in the incidence of many cancer types indicate the existence of carcinogen exposures that have not been identified by conventional epidemiology yet potentially make a substantial contribution to cancer burden1. This pertains to clear cell renal cell carcinoma (ccRCC), fo...

2024-03-26 | MTBLS9394 | MetaboLights
UnknownPitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer.
Stromal tumor-infiltrating lymphocytes (sTILs) are important prognostic and predictive biomarkers in triple-negative (TNBC) and HER2-positive breast cancer. Incorporating sTILs into clinical practice necessitates reproducible assessment. Previously developed standardized scoring guidelines have been...
S-EPMC7217863 | biostudies-literature
UnknownThe tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group.
The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed death-ligand 1 (PD-L1). These patients may potenti...
S-EPMC8636568 | biostudies-literature
UnknownApplication of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials.
Stromal tumor-infiltrating lymphocytes (sTILs) are a potential predictive biomarker for immunotherapy response in metastatic triple-negative breast cancer (TNBC). To incorporate sTILs into clinical trials and diagnostics, reliable assessment is essential. In this review, we propose a new concept, na...
S-EPMC7217941 | biostudies-literature
Sort   by:  
 Page size